Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats.

IF 1.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Chon Kit Pun, Ching-Chih Chang, Chiao-Lin Chuang, Hui-Chun Huang, Shao-Jung Hsu, Yi-Hsiang Huang, Ming-Chih Hou, Fa-Yauh Lee
{"title":"Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats.","authors":"Chon Kit Pun,&nbsp;Ching-Chih Chang,&nbsp;Chiao-Lin Chuang,&nbsp;Hui-Chun Huang,&nbsp;Shao-Jung Hsu,&nbsp;Yi-Hsiang Huang,&nbsp;Ming-Chih Hou,&nbsp;Fa-Yauh Lee","doi":"10.1097/JCMA.0000000000000959","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Portal hypertension develops along with the progression of liver cirrhosis. Natriuretic peptides have been shown to reduce portal pressure but concomitantly activate the renin-angiotensin-aldosterone system (RAAS). Angiotensin receptor-neprilysin inhibitors (ARNIs) upregulate natriuretic peptides and avoid the adverse effects of RAAS activation. ARNIs have been shown to reduce portal pressure in rats with pre-hepatic portal hypertension, which involves relatively little liver injury. This study aimed to evaluate the relevant effects of an ARNI in rats with both liver cirrhosis and portal hypertension.</p><p><strong>Methods: </strong>Male Sprague-Dawley rats received common bile duct ligation to induce liver cirrhosis and portal hypertension. Sham-operated rats served as surgical controls. All rats were randomly allocated into three groups to receive distilled water (vehicle), LCZ696 (an ARNI), or valsartan for 4 weeks. Portal hypertension and relevant derangements were assessed after treatment.</p><p><strong>Results: </strong>Portal hypertension and hyperdynamic circulation developed in the cirrhotic rats. In the rats with cirrhosis and portal hypertension, both LCZ696 and valsartan reduced portal hypertension, mean arterial pressure, and systemic vascular resistance. The decrease in portal pressure was highly associated with the reduction in arterial pressure and systemic vascular resistance. Blood flow in hepatic, splanchnic, and portosystemic collateral systems was not altered. LCZ696 did not significantly influence liver injury or plasma cytokine levels. Liver fibrosis and splanchnic angiogenesis were not affected.</p><p><strong>Conclusion: </strong>ARNI treatment exerted portal pressure lowering effects via peripheral vasodilatation and decreasing systemic arterial pressure in the rats with liver cirrhosis and portal hypertension. Caution should be taken when using ARNIs in liver cirrhosis.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 9","pages":"786-794"},"PeriodicalIF":1.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Chinese Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCMA.0000000000000959","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Portal hypertension develops along with the progression of liver cirrhosis. Natriuretic peptides have been shown to reduce portal pressure but concomitantly activate the renin-angiotensin-aldosterone system (RAAS). Angiotensin receptor-neprilysin inhibitors (ARNIs) upregulate natriuretic peptides and avoid the adverse effects of RAAS activation. ARNIs have been shown to reduce portal pressure in rats with pre-hepatic portal hypertension, which involves relatively little liver injury. This study aimed to evaluate the relevant effects of an ARNI in rats with both liver cirrhosis and portal hypertension.

Methods: Male Sprague-Dawley rats received common bile duct ligation to induce liver cirrhosis and portal hypertension. Sham-operated rats served as surgical controls. All rats were randomly allocated into three groups to receive distilled water (vehicle), LCZ696 (an ARNI), or valsartan for 4 weeks. Portal hypertension and relevant derangements were assessed after treatment.

Results: Portal hypertension and hyperdynamic circulation developed in the cirrhotic rats. In the rats with cirrhosis and portal hypertension, both LCZ696 and valsartan reduced portal hypertension, mean arterial pressure, and systemic vascular resistance. The decrease in portal pressure was highly associated with the reduction in arterial pressure and systemic vascular resistance. Blood flow in hepatic, splanchnic, and portosystemic collateral systems was not altered. LCZ696 did not significantly influence liver injury or plasma cytokine levels. Liver fibrosis and splanchnic angiogenesis were not affected.

Conclusion: ARNI treatment exerted portal pressure lowering effects via peripheral vasodilatation and decreasing systemic arterial pressure in the rats with liver cirrhosis and portal hypertension. Caution should be taken when using ARNIs in liver cirrhosis.

双重血管紧张素受体和奈普利素抑制剂通过外周血管扩张和降低全身动脉压降低肝硬化大鼠的门静脉压力。
背景:门脉高压是随着肝硬化的进展而发展的。利钠肽已显示降低门静脉压力,但同时激活肾素-血管紧张素-醛固酮系统(RAAS)。血管紧张素受体-神经利尿素抑制剂(ARNIs)上调利钠肽,避免RAAS激活的不良影响。ARNIs已被证明可以降低肝前门静脉高压大鼠的门静脉压力,而肝前门静脉高压涉及的肝损伤相对较小。本研究旨在评价ARNI对肝硬化和门脉高压大鼠的相关作用。方法:雄性Sprague-Dawley大鼠行胆总管结扎术,诱导肝硬化和门静脉高压症。假手术大鼠作为手术对照。所有大鼠随机分为三组,分别给予蒸馏水(载药)、LCZ696 (ARNI)或缬沙坦治疗4周。治疗后评估门静脉高压症及相关紊乱。结果:肝硬化大鼠出现门脉高压和高动力循环。在肝硬化和门静脉高压症大鼠中,LCZ696和缬沙坦均能降低门静脉高压症、平均动脉压和全身血管阻力。门静脉压的降低与动脉压和全身血管阻力的降低高度相关。肝、内脏和门静脉侧枝系统的血流没有改变。LCZ696对肝损伤及血浆细胞因子水平无显著影响。肝纤维化和内脏血管生成未受影响。结论:ARNI治疗对肝硬化门脉高压大鼠具有外周血管舒张、降低全身动脉压的降门静脉压作用。在肝硬化患者中使用ARNIs时应谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the Chinese Medical Association
Journal of the Chinese Medical Association MEDICINE, GENERAL & INTERNAL-
CiteScore
6.20
自引率
13.30%
发文量
320
审稿时长
15.5 weeks
期刊介绍: Journal of the Chinese Medical Association, previously known as the Chinese Medical Journal (Taipei), has a long history of publishing scientific papers and has continuously made substantial contribution in the understanding and progress of a broad range of biomedical sciences. It is published monthly by Wolters Kluwer Health and indexed in Science Citation Index Expanded (SCIE), MEDLINE®, Index Medicus, EMBASE, CAB Abstracts, Sociedad Iberoamericana de Informacion Cientifica (SIIC) Data Bases, ScienceDirect, Scopus and Global Health. JCMA is the official and open access journal of the Chinese Medical Association, Taipei, Taiwan, Republic of China and is an international forum for scholarly reports in medicine, surgery, dentistry and basic research in biomedical science. As a vehicle of communication and education among physicians and scientists, the journal is open to the use of diverse methodological approaches. Reports of professional practice will need to demonstrate academic robustness and scientific rigor. Outstanding scholars are invited to give their update reviews on the perspectives of the evidence-based science in the related research field. Article types accepted include review articles, original articles, case reports, brief communications and letters to the editor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信